Figures & data
Table 1 Kaplan-Meier estimates of the proportion of patients (95% confidence intervals) with control of inflammation and control of inflammation plus corticosteroid-sparing success as reported at various time points across different studies.
Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–509.e2. Gangaputra S, Newcomb CW, Liesegang TL, et al. Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–98.e1. Pujari SS, Kempen JH, Newcomb CW et al., Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117:356–365. Kaçmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–584. Daniel E, Thorne JE, Newcomb CW et al., Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149:423–32.e1. Kempen JH, Altaweel MM, Holbrook JT, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology.2011; 118:1916–1926. Epub 2011 Aug 15. Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;18–26.